| A Phase I Study of LX22001 for Injection in Healthy Subjects (NCT06561542) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2024-08-05 |
| Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin (NCT05915871) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2023-03-23 |
| Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (NCT05577468) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2022-10-30 |
| Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation (NCT05151328) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2022-03-18 |
| Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer (NCT05010954) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2021-10-18 |
| A Phase I Study of LX-039 Tablets (NCT04097756) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2020-01-07 |
| A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks (NCT03591653) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2018-10-29 |
| Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis (NCT03615677) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2018-10-24 |
| A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability. (NCT03458650) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2018-03-19 |